Harnessing insights from the AML biology, novel therapeutic modalities such as inhibition of cyclin-dependent kinases and B-cell lymphoma 2 (BCL2) proteins are emerging wherein therapeutic strategies can be reframed regardless of patient fitness or specific biological subgroup harboring genetic mutations [7–9]. The gene discussed is BCL2; the disease is acute myeloid leukemia.